Literature DB >> 21115577

The etiology of hepatocellular carcinoma and consequences for treatment.

Arun J Sanyal1, Seung Kew Yoon, Riccardo Lencioni.   

Abstract

Most patients with hepatocellular carcinoma (HCC) have liver cirrhosis, which develops following long periods of chronic liver disease. Cirrhosis is characterized by a decrease in hepatocyte proliferation, indicating an exhaustion of the regenerative capacity of the liver, and results in an increase in fibrous tissue and a destruction of liver cells, which may ultimately lead to the development of cancerous nodules. Half of all cases of HCC are associated with hepatitis B virus infection, with a further 25% associated with hepatitis C virus. Other risk factors for developing HCC include alcoholic liver disease, nonalcoholic steatohepatitis, intake of aflatoxin-contaminated food, diabetes, and obesity. There are multiple factors involved in the etiology of HCC, all of which have a direct impact on patient characteristics and disease course, and although a causative agent can often be identified, HCC remains an extremely complex condition associated with a poor prognosis. Additionally, the geographic variation in etiology means that information from different countries is needed in order to optimize surveillance methods and develop effective chemoprevention strategies. Unfortunately, there are still many gaps in our current understanding, and further research efforts are needed to fully elucidate the diverse mechanisms involved in the pathogenesis of HCC and offer optimal prevention strategies for those at risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115577     DOI: 10.1634/theoncologist.2010-S4-14

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  167 in total

1.  Identification of osteopontin as a novel marker for early hepatocellular carcinoma.

Authors:  Sufen Shang; Amelie Plymoth; Shaokui Ge; Ziding Feng; Hugo R Rosen; Suleeporn Sangrajrang; Pierre Hainaut; Jorge A Marrero; Laura Beretta
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

Review 2.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

3.  Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study.

Authors:  Hla-Hla Thein; Edwin Khoo; Michael A Campitelli; Ahmad Zaheen; Qilong Yi; Prithwish De; C C Earle
Journal:  CMAJ Open       Date:  2015-04-02

4.  Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway.

Authors:  Kelli A Lytle; Christopher M Depner; Carmen P Wong; Donald B Jump
Journal:  J Lipid Res       Date:  2015-08-27       Impact factor: 5.922

Review 5.  Epigenetics of hepatocellular carcinoma: role of microRNA.

Authors:  Sharad Khare; Qiong Zhang; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

6.  Serum NOX2 as a new biomarker candidate for HBV-related disorders.

Authors:  Yuan Xiong; Yuanyuan Ye; Pu Li; Yahui Xiong; Jinju Mao; Yong Huang; Weixian Chen; Bo Wang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 7.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

8.  8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.

Authors:  Mei-Fang Quan; Li-Hong Xiao; Zhi-Hong Liu; Hui Guo; Kai-Qun Ren; Fei Liu; Jian-Guo Cao; Xi-Yun Deng
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

9.  The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.

Authors:  Michael Schonfeld; Jie Zhao; Amberly Komatz; Steven A Weinman; Irina Tikhanovich
Journal:  J Biol Chem       Date:  2020-04-03       Impact factor: 5.157

10.  Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3 cm.

Authors:  Alessia Guarneri; Pierfrancesco Franco; Elisabetta Trino; Daniela Campion; Riccardo Faletti; Stefano Mirabella; Silvia Gaia; Riccardo Ragona; Margherita Diotallevi; Giorgio Saracco; Mauro Salizzoni; Umberto Ricardi; Patrizia Carucci
Journal:  Med Oncol       Date:  2016-08-26       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.